A New Labeling Method of 99mTc-PSMA-HBED-CC

Sep 29, 2026

Uploaded by acoobca

A new in-house radiolabeling approach develops 99mTc-PSMA-HBED-CC as an accessible alternative to 68Ga-PSMA-HBED-CC for prostate cancer PET imaging. The method adds 99mTc-pertechnetate to PSMA-HBED-CC with 4% SnCl2·2H2O, then heats at 100°C for 15 minutes. Labeling conditions are optimized to maximize radiochemical yield, while chelation completeness is monitored by instant thin layer chromatography and stability is assessed after preparation.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages6

Reading Time15 min

AccessFree to download

Abstract

Keywords

Objective

Methods

Results

Conclusion

Introduction

Article published online: 2025-06-26 Original Article 319 A New Labeling Method of 99mTc-PSMA-HBED-CC Benchamat Phromphao 1,2 Shuichi Shiratori3 1 Medical Physics Program, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 2 Chulalongkorn University Biomedical Imaging Group, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 3 Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand World J Nuclear Med 2025;24:319–324. Address for correspondence Shuichi Shiratori, PhD, 2 Wanglang Road, Siriraj Sub-District, Bangkok Noi, Bangkok, 10700, Thailand (e-mail: [shuichi.shi@mahidol.ac.th](shuichi.shi@mahidol.ac.th)). Abstract Keywords ► prostate cancer ► PSMA-HBED-CC ► PSMA-11 ► technetium-99m ► 99mTc-PSMA-HBED-CC Objective 68Ga-PSMA-HBED-CC (68Ga-PSMA-11) was approved by the U. S. Food and Drug Administration as the ﬁrst prostate-speciﬁc membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging drug for patients with prostate cancer. However, the utility of 68Ga-PSMA-HBED-CC may be limited due to PET/CT or PET/MR accessibility and 68GaCl3 availability produced from 68Ge/68Ga generator or cyclotron. Thus, in-house preparation of 99mTc-PSMA-HBED-CC was developed as an alternative to 68Ga-PSMA-HBED-CC to be ubiquitous and affordable in the worldwide population. Methods A solution of 99mTc-pertechnetate was added to PSMA-HBED-CC and 4% SnCl2·2H2O in a 10-mL sterile vial. The mixture was heated at 100°C for 15 minutes and then allowed to cool to room temperature. Labeling conditions were optimized to maximize the radiochemical yield of 99mTc-PSMA-HBED-CC. The chelation completeness was monitored using instant thin layer chromatography, and the stability of 99mTc-PSMA-HBED-CC was subsequently evaluated. Results The radiolabeling of 99mTc-PSMA-HBED-CC was successful using the appropriate amount of 10 µg PSMA-HBED-CC 3 µg SnCl2·2H2O and 99mTc-pertechnetate 370 MBq at 100°C for 15 minutes, yielded the best result in high radiochemical yield (71.49 􀀁 2.42%), radiochemical purity (98.29 􀀁 2.65%), and speciﬁc activity of 37.84 􀀁 1.47 GBq/µmol. 99mTc-PSMA-HBED-CC is stable with radiochemical purity of more than 95% within 4 hours at room temperature. Conclusion A new labeling method of 99mTc-PSMA-HBED-CC was developed. Quality control parameters of 99mTc-PSMA-HBED-CC met the criteria in accordance with the European Pharmacopoeia. Introduction Prostate cancer is the most common malignancy found in men and the second leading cause of cancer death worldwide.1 Over the past two decades, the initial diagnosis and follow-up have been serum prostate-speciﬁc antigen levels, digital rectal examination, and some conventional imaging article published online June 26, 2025 DOI [https://doi.org/](https://doi.org/)[ ](https://doi.org/)10.1055/s-0045-1809921 . ISSN 1450-1147. techniques including ultrasound, computed tomography, magnetic resonance imaging, and bone scintigraphy, but none provides highly speciﬁc and sensitive detection. Although transrectal ultrasound-guided prostate biopsy is currently accepted as the gold standard to provide the histopathological diagnosis of prostate cancer,2 it is an invasive procedure that resulted in a risk of side effects © 2025 . The Author(s) . This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited.([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)) Thieme Medical and Scientiﬁc Publishers Pvt. Ltd. , A-12, 2nd Floor, Sector 2, Noida-201301 UP, India 320 New Labeling Method of 99mTc-PSMA-HBED-CC Phromphao, Shiratori and the accuracy of diagnosis. The accurate deﬁnition of tumor burden and its sta

FAQs

Why develop 99mTc-PSMA-HBED-CC instead of using 68Ga-PSMA-HBED-CC?

68Ga-PSMA-HBED-CC utility may be limited by PET/CT or PET/MR accessibility and by the availability of 68GaCl3. An in-house 99mTc labeling method aims to make the tracer more ubiquitous and affordable worldwide.

How is 99mTc-PSMA-HBED-CC prepared in the study?

99mTc-pertechnetate is added to PSMA-HBED-CC with 4% SnCl2·2H2O in a sterile vial, followed by heating at 100°C for 15 minutes and cooling to room temperature. Labeling conditions are optimized to improve radiochemical yield.

What performance metrics and stability results are reported?

Using 10 µg PSMA-HBED-CC, 3 µg SnCl2·2H2O, and 370 MBq 99mTc-pertechnetate at 100°C for 15 minutes yields a radiochemical yield of 71.49 ± 2.42%, radiochemical purity of 98.29 ± 2.65%, and specific activity of 37.84 ± 1.47 GBq/µmol. Stability is reported with radiochemical purity above 95% within 4 hours at room temperature.

Sep 29, 2026

Uploaded by acoobca